Takeda Divests Eye Drug to Novartis for $5.3 Billion

In January, Takeda Pharmaceutical announced plans to sell about $10 billion worth of assets to offset some of the debt the company garnered in its $62 billion acquisition of Shire. On Wednesday, the Osaka, Japan company announced divestitures worth about $5.7 billion. Takeda entered into agreements with Swiss pharma giant Novartis and Ethicon.
Read more...

;